Genitourinary Cancers Research: Immunotherapy, Gut Microbiome, and Liquid Biopsy

February 13, 2017
Monika Sharda, ASCO staff

The 2017 Genitourinary Cancers Symposium takes place this week in Orlando, Florida, from February 16 to 18. In this podcast, Sumanta (Monty) Pal, MD, talks about 3 studies that will be presented at the symposium. share on twitter

  • A small study that showed that some patients with advanced kidney cancer were able to stop immunotherapy early without having the disease worsen [1:22].

  • Research on a potential connection between a person’s gut bacteria, or “gut microbiome,” and how well immunotherapy works. In the study discussed here, researchers found that immunotherapy was less effective for people with kidney cancer who had used antibiotics less than a month before starting treatment [2:47].

  • A study on free-floating cancer DNA from blood tests showed that these tests could help identify new molecular targets in advanced prostate cancer. These tests are often called circulating tumor DNA tests and may also be referred to as a “liquid biopsy” [4:15].

Dr. Pal is co-director of City of Hope's Kidney Cancer Program, the head of the kidney and bladder cancer disease team at the institution, and the Cancer.Net Associate Editor for Genitourinary Cancers.

This is a prerecorded audio podcast. It can be listened to online or downloaded to your computer. A transcript of this podcast is also available. For more information, visit the Cancer.Net podcast page.

Share your thoughts on this blog post on Cancer.Net's Facebook and Twitter.